Navigation Links
Data Published in Circulation Journal Show OrbusNeich's Genous™ Stent Is Safe and Effective in Elderly Patients
Date:10/25/2011

HONG KONG, Oct. 25, 2011 /PRNewswire/ -- OrbusNeich today announced the publication of 12-month follow-up data from the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) registry in Circulation Journal that show the Genous Stent is safe and effective in elderly patients.

In the study, no significant difference in stent thrombosis (ST) was observed at 12 months between elderly patients (aged 65 or older) and younger patients. The target lesion revascularization (TLR) rate was not significantly higher with increasing age. Target vessel failure (TVF), the main outcome of the study, was observed more often in elderly patients; TVF occurred in 11.7 percent of patients over the age of 75, in 8.8 percent of patients between the ages of 65 and 74, and in 7 percent of patients younger than 65. The increased rate of TVF in elderly patients was driven mainly by increased mortality.

"Early discontinuation of dual antiplatelet therapy (DAPT) has been identified as a major predictor for the occurrence of ST, and for this reason the elderly are at a particularly high-risk for ST due to their expected non-compliance with DAPT," said Dr. Andres Iniguez of the University of Vigo, Spain. "The elderly comprise an important subgroup of patients for whom long-term DAPT may not be advisable, and these data show that in patients over 65 the Genous Stent was safe and did not lead to an increased risk of ST despite their lower compliance."

The registry's main outcome was TVF at 12-month follow-up, defined as the composite of cardiac death or myocardial infarction (MI) unless unequivocally attributable to a non-target vessel and target vessel revascularization (TVR). Secondary outcomes were the composite of cardiac death, MI and clinically-indicated TLR, the individual outcomes all-cause death, cardiac death, MI (non-Q-wave or Q-wave), TLR, TVR, ST, major and minor bleeding and stroke.

e-HEALING, a multi-center, worldwide prospective clinical registry conducted at 144 centers in 31 countries outside of the United States, included 4,939 patients with at least one lesion suitable for non-urgent percutaneous coronary intervention (PCI) and Genous Stent implantation. In the patient population, 2,651 were under the age of 65, 1,403 were between the ages of 65 and 74, 794 were between the ages of 75 and 84, and 75 were over the age of 85. Elderly patients were defined as patients over the age of 65 and the very elderly as patients over the age of 75.

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 6,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and the Genous technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedical.


'/>"/>
SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition ... their offering. ... The global lifestyle drugs market to grow at a CAGR of ... Lifestyle Drugs Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:3/29/2017)... Calif. , March 29, 2017 Varian Medical ... will report results for the second quarter of fiscal year ... 26, 2017.  The news release will be followed by a ... The news release and a link to the conference call ... www.varian.com/investor .  To access the teleconference call and replay: ...
(Date:3/29/2017)... Calif. , March 29, 2017  Designers of ... significantly reduce solution size by 50% and extend battery ... ) power management integrated circuit (PMIC) from Maxim Integrated ... PMIC supports a low input voltage of just 0.7V ... Air and Silver Oxide, as well as the more ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... March 30, 2017 , ... The ... offerings of corporate finance programs to address the increasingly complex educational needs of ... increase their knowledge of sophisticated corporate finance and will increase their ability to ...
(Date:3/30/2017)... ... ... An inventor and manicurist from Greet, S.C., wants to offer people a new way to ... clean and healthy feet, so I know the importance of proper foot care," he said. ... the FOOT-TRAN SYSTEM." , The FOOT-TRAN SYSTEM enables a user to clean and exfoliate the ...
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, a leader in ... Hospital Readmissions Through Discharge Planning ” with noted expert Sue Dill Calloway, RN, ... discusses strategies to prevent readmissions in light of the most recent programs at ...
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week of March, Chad ... to eligible individuals in the local community. , Colon cancer is the second ... detect colon cancer while it is small, confined and easier to treat. If you ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
Breaking Medicine News(10 mins):